Moffitt Cancer Center | Strategic Alliance Partners

Omar Castaneda Puglianini, MD, discusses results from the phase 1b/2 CARTITUDE-1 trial evaluating ciltacabtagene autoleucel in patients with relapsed/refractory multiple myeloma. 

Rachid Baz, MD, discusses the role of alkylating agents in relapsed/refractory multiple myeloma.

Bijal Shah, MD, MS, discusses the FDA approval of brexucabtagne autoleucel in relapsed/refractory B-cell acute lymphoblastic leukemia.

Brandon Blue, MD, discusses the utility of carfilzomib in relapsed/refractory multiple myeloma.

Dr. Scott and Dr. Torres-Roca discuss their research of a pooled retrospective analysis exploring genomic-adjusted radiation dose–based radiation therapy in solid tumors and what using genomics to guide radiation dosing decisions could mean for oncology practices.

Rohit Jain, MD, MPH, discusses the data from the phase 3 JAVELIN Bladder 100 trial examining avelumab as maintenance therapy following response or stable disease with first-line platinum-based chemotherapy in patients with advanced or metastatic urothelial cancer.

Rachid Baz, MD, discusses the utility of venetoclax in patients with heavily pretreated multiple myeloma.

Rohit Jain, MD, MPH, discusses the nuances of treatment selection for patients with platinum-eligible vs -ineligible metastatic urothelial carcinoma, the current state of immunotherapy in this disease, and factors to consider during the decision-making process in RCC and mCRPC.

Martine Extermann, MD, PhD, discusses the significance of novel treatment options in HER2-positive breast cancer.

Ricardo Costa, MD, MSc, discusses the patient population included in the phase 3 OlympiA trial in breast cancer.

Robert Wenham, MD, MS, FACOG, FACS, discusses the potential for immunotherapy in ovarian cancer.

Jingsong Zhang, MD, PhD, discusses the current state of risk stratification in metastatic castration-resistant prostate cancer.

Javier Torres-Roca, MD, discusses optimizing radiation therapy with genomic-adjusted radiation dose–based radiotherapy dosing in oncology.

Nivolumab followed by treatment with tumor-infiltrating lymphocytes was generally safe and found to have clinical benefit in patients with metastatic non–small cell lung cancer.

Martine Extermann, MD, PhD, shares advice for selecting among the CDK4/6 available for the treatment of patients with hormone receptor–positive breast cancer.

Christine Sam, MD, discusses strategies for sequencing tucatinib and fam-trastuzumab deruxtecan-nxki in the treatment of patients with HER2-positive breast cancer.

Hung Khong, MD, underscores the importance of testing for BRCA mutations in patients with breast cancer. 

Due to the potency of CAR T-cell therapies and the associated adverse events that can to arise in patients receiving this type of treatment, oncology nurses need to be educated on how to best identify and manage these AEs.

Christine Sam, MD, discusses therapeutic developments in metastatic HER2-positive breast cancer.

The widening treatment paradigm for various breast cancer subtypes is yielding improved survival with more tailored strategies.

Martine Extermann, MD, PhD, discusses the utility of single-agent trastuzumab in HER2-positive breast cancer.

Christine Sam, MD, shares strategies to manage interstitial lung disease experienced with fam-trastuzumab deruxtecan-nxki in patients with HER2-positive breast cancer.

Moffitt Cancer Center is currently working to develop a host of novel therapeutic treatments within the breast cancer space, from immunotherapeutics to personalized cancer vaccines.

David Sallman, MD, discusses the efficacy of pevonedistat plus azacitidine in higher-risk myelodysplastic syndrome.

Ricardo Costa, MD, MSc, discusses ongoing research efforts in triple-negative breast cancer.

David Sallman, MD, discusses the role of hypomethylating agents in the treatment of patients with higher-risk myelodysplastic syndrome, the promise of pevonedistat in this population, the hunt for biomarkers of response to treatment, and remaining areas of unmet need to address with future efforts.

Jing-Yi Chern, MD, ScM, discusses outcomes with PARP inhibitors in patients with recurrent ovarian cancer.

Sarabdeep “Sabi” Singh has been named executive vice president and chief operating officer of Moffitt Cancer Center, the only National Cancer Institute-designated Comprehensive Cancer Center based in Florida.

David Sallman, MD, discusses unmet needs in the treatment of patients with higher-risk myelodysplastic syndromes.

Bijal Shah, MD, MS, discusses efforts to combat resistance to BTK inhibitors in patients with mantle cell lymphoma.